Why literature monitoring needs a better workflow
Every week, a pharmacovigilance team has to answer the same question: did anything published since last week describe an adverse event for one of our products? Medical literature is a recognized source of individual case safety reports (ICSRs). Under EU GVP Module VI, marketing authorization holders are expected to screen it at least weekly; the reporting clock starts as soon as the team becomes aware of a publication containing a valid case.
The work does not let up. Searches run across MEDLINE, Embase, subject-specific databases and local journals. The same article surfaces in three sources, then again the following week. Most hits are irrelevant. A missed case, though, is a patient-safety gap and an inspection finding waiting to happen.
AI can absorb much of that volume. The real question is how to use it without losing the traceability inspectors expect. What follows is the anatomy of a literature workflow that does both: seven stages from scheduled search to medical sign-off, with an expert verifying every decision that carries regulatory weight.
The seven stages of an AI-enabled pharmacovigilance literature workflow
Each stage below hands a cleaner, smaller set of records to the next. Automation does the repetitive work. Reviewers make the calls that matter.
1. Scheduled searches
Product and adverse-event search strategies run automatically on a set schedule, across global and local literature. No one has to remember to rerun a search on Monday morning, and every run is recorded. Teams without in-house librarians can have DistillerSR Library Services build PRESS-validated search strategies to start from.
2. Deduplicate references
The same paper often appears in several databases and resurfaces in later weeks. Deduplication checks new hits across all sources and against prior weeks’ results, then flags or removes the duplicates. Reviewers see each potential case once, so no case is processed twice.
3. AI classifiers and labelling
AI Classifiers label each reference before a reviewer opens it: potential ICSR, special situations such as pregnancy or overdose, and other safety signals. Those labels let teams route and prioritize work, so likely cases rise to the top of the queue.
4. Smart Screening, with the reviewer in the loop
Smart Screening applies regulatory-grade AI to title and abstract screening, and reviewers confirm relevance. Every decision is logged with full data provenance. Teams can run dual review and add Secondary AI Error Checking, where an independent AI validates screening decisions.
5. Automated full-text retrieval
Full texts arrive automatically through direct integrations with CCC, CuratorCR, PMC, and Article Galaxy, with copyright compliance built in. Day 0 is tracked at this stage, so the reporting clock is visible from the moment the article is in hand.
6. Smart Case Extraction, AI-proposed and reviewer-verified
AI proposes case data from the full text. Conditional workflows adapt the extraction form to the context of each case. A reviewer verifies every proposed data point before the case moves forward.
7. Medical review
A medical reviewer confirms case validity and signs off. That sign-off is captured in the audit trail, down to the individual reviewer and timestamp. The final call on every case stays with a qualified expert.
Export to safety database
Once medical review signs off, validated cases transfer to the safety database through E2B(R3) or export. From there they feed ICSR submission to the FDA, EMA and Health Canada, signal management, and downstream reports such as PSURs/PBRERs and DSURs.
The workflow also runs in the other direction. CuratorCR and the internal library sit alongside the external databases as literature sources, so articles the organization has already reviewed are recognized instead of reprocessed. That is evidence reuse in practice: Extract it Once. Reuse it Everywhere.
Both DistillerSR Agentic AI and Smart Chat extend that reuse to the rest of the safety team. Both are grounded, secure chat interfaces to the curated, audited safety literature, so a signal reviewer can ask a question and get an answer drawn from validated evidence rather than the open web.
Why the expert stays in the loop
Look at where the human checkpoints sit: screening, smart evidence extraction and medical review. Those are the three decisions with regulatory consequence. Everything else, from running searches to fetching full texts, is volume work that automation handles well.
That split reflects DistillerSR’s Expert-in-the-Loop approach: research augmented, not replaced. AI speeds up each stage. Experts validate the outputs that determine whether a case is reported, and when. Accuracy data supports the design. In an Eli Lilly assessment, DistillerSR AI achieved a mean accuracy of 90%. That is strong performance, and it is also why a reviewer still confirms every case.
The result is a workflow built for inspection:
- Complete audit trail: every decision is tracked to the individual reviewer and timestamp.
- Regulatory alignment: adherence to FDA 21 CFR Part 11, with workflows aligned to GVP Module VI.
- Clock visibility: reporting-clock and SLA tracking from Day 0 onward.
- Data security: customer data stays in the platform, and no AI models are trained on it.
The takeaway
An AI-enabled pharmacovigilance workflow is not one model making one decision. It is a chain: search, deduplicate, classify, screen, extract, and review. Each link is either automated with a record behind it or verified by an expert. When every link is traceable, speed and compliance stop pulling against each other.
DistillerSR brings that chain into one platform, from the first scheduled search to the handoff to your safety database.







